NCT04073589View on ClinicalTrials.gov

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

September 26, 2019

Study Completion Date

September 26, 2019

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

ARGX-113 with rHuPH20

subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)

Trial Locations (1)

Unknown

Investigator Site, Groningen

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY

NCT04073589 - Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects | Biotech Hunter | Biotech Hunter